Business
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
WATERTOWN, Mass., May 12, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2025.
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2190,"height":732,"url":"https://media.zenfs.com/en/business-wire.com/9071364ba324c0a1311783e75c6dbe3d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KARWhDKErEVsNrkIiGxaSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9071364ba324c0a1311783e75c6dbe3d","width":960,"height":321},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/eHFmhZQI2OsA9aLJc3SdbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9071364ba324c0a1311783e75c6dbe3d","width":1200,"height":401}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Met Target Enrollment for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV); On Track to Report Topline Data in Late 3Q 2025","length":180,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"STAT6 Program Progressing with Plans to Select a Development Candidate in 2H 2025","length":81,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"IND Enabling Studies of KIT Inhibitor EPS-1421 Ongoing","length":54,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash and Marketable Securities Totaling $193.4 Million at March 31, 2025, Further Strengthened by a $33.8 Million Federal Income Tax Refund Received in April 2025","length":162,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":477,"olType":false},{"type":"text","content":"WATERTOWN, Mass., May 12, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2025.","length":308,"tagName":"p"},{"type":"text","content":""Throughout the fiscal second quarter, Enanta remained squarely focused on executing across our virology and immunology pipeline. We are thrilled to have enrolled our target of 180 patients in RSVHR, a Phase 2 study of zelicapavir in high-risk adults infected with RSV, and plan to complete enrollment in late May to capture the remainder of the current Northern Hemisphere RSV...